boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us   news clarus closes a  million fund vbi vaccines announces phase  clinical program for scibvac hepatitis b vaccine more news  copyright   clarus ventures llc  all rights reserved boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us managing directors emmett cunningham nicholas galakatos robert w liptak scott requadt nicholas j simon michael steinmetz kurt c wheeler partners barry gertz michele park principalsadvisorsassociates dennis henner edward scolnick jeffrey leiden william young robert debenedetto kiran reddy ari brettman lazar dimitrov staff copyright   clarus ventures llc  all rights reserved clarus extranet clarus extranet email password forgot your password click here information data and documents contained herein may be confidential and are for clarus internal use only boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us   clarus buzz  events nature biotechnology feature feature article in nature biotechnology academic spinouts of  volume  number  may  academic spinouts of    copyright   clarus ventures llc  all rights reserved   boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us   about us clarus is a leading global investment firm dedicated to life sciences founded in  by a team of accomplished investment and operating professionals clarus manages over  billion and has invested in more than  private and public companies in the biotechnology medical device and diagnostic spaces in every investment clarus employs a handson approach and leverages its scientific and clinical development expertise as well as the ability to adapt to an everchanging investment landscape clarus strives to generate outstanding returns for its investors by identifying and financing innovative medicines that improve people’s lives copyright   clarus ventures llc  all rights reserved   boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us fund all clarus lifesciences i lp clarus lifesciences ii lp clarus lifesciences iii lp status all active exited sector all biotechnology diagnostics  tools medical device type all public private defined exits  royalties copyright   clarus ventures llc  all rights reserved   fund clarus lifesciences ii lp sector biotechnology type public team  nicholas j simon michele park achillion pharmaceuticals inc nasdaq achn achillion is a biopharmaceutical company focused on the discovery development and commercialization of novel small molecule inhibitors targeting infectious disease pipeline programs include a firstinclass hcv replicase inhibitor partnered with gilead and an hcv protease inhibitor additional drug candidates target treatment of hiv and bacterial infections achillion website fund clarus lifesciences ii lp sector biotechnology type public team  dennis henner emmett cunningham aerie pharmaceuticals inc nasdaq aeri aerie pharmaceuticals is a privately held clinicalstage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma aerie’s internal research and development engine has generated an innovative glaucoma pipeline in addition to ar the company’s rhokinase rock inhibitor the pipeline includes ar a novel product candidate with a dual mechanism of action that represents the first of a new proprietary class of glaucoma drugs ar is currently in preclinical indenabling studies aerie website  aerie pharmaceuticals reports roclatantm phase b results achieve all clinical endpoints  aerie pharmaceuticals announces pricing of initial public offering fund clarus lifesciences iii lp sector biotechnology type private team  william young dennis henner emmett cunningham annexon biosciences annexon is developing novel antibody therapeutics for neurodegenerative and autoimmune disorders annexon’s most advanced program targets huntington’s disease annexon website  annexon bioscience closes m series a funding for novel approach to neurodegenerative and autoimmune diseases fund clarus lifesciences i lp sector biotechnology type public team  nicholas j simon dennis henner emmett cunningham avanir pharmaceuticals inc nasdaq avnr avanir pharmaceuticals nasdaqavnr is focused on developing acquiring and commercializing novel therapeutic products for the treatment of chronic diseases avanir’s products and product candidates address therapeutic markets that include central nervous system disorders inflammation and infectious disease zenvia™ is avanirs lead product candidate for the treatment of pseudobulbar affect pba also known as involuntary emotional expression disorder ieed avanir website fund clarus lifesciences ii lp sector biotechnology type defined exit team  robert w liptak kurt c wheeler dennis henner emmett cunningham avillion avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products we offer a compelling opportunity to partner late phase therapeutic projects for approval in the eu and us and to accelerate their availability to the market avillion website  avillion signs clinical codevelopment agreement with merck to advance anti il af nanobody® in psoriasis  pfizer and avillion announce positive topline results for phase  bfore study of bosulif for firstline treatment  avillion announces dosing of first patients in phase  bfore trial to assess bosulif® bosutinib as firstline treatment for patients with chronic myelogenous leukemia  avillion elects ulf wiinberg ceo of lundbeck as chairman of its board of directors  avillion group partners with pfizer to codevelop bosulif® bosutinib as firstline treatment for patients with chronic myelogenous leukemia fund clarus lifesciences iii lp sector biotechnology type private team  scott requadt avrobio avrobio inc a leader in lentiviralbased gene therapies is a clinical stage company developing transformative lifechanging therapies that have the potential to transform patients’ lives in a single dose the catalyst for creating avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies the patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease avrobio website  aiming for durability avrobio inc featured in  issue of biocentury weekly fund clarus lifesciences ii lp sector biotechnology type public team  scott requadt nicholas galakatos catabasis pharmaceuticals inc nasdaq catb catabasis is an early stage biopharmaceutical company led by experienced entrepreneurs that is developing nces that incorporate and amplify the beneficial effects of omega fatty acids it is advancing multiple proprietary small molecule candidates for the treatment of metabolic disease and inflammation catabasis website  catabasis pharmaceuticals phase  data on edasalonexent cat a potential diseasemodifying therapy being developed for duchenne muscular dystrophy published in the journal of clinical pharmacology  catabasis pharmaceuticals provides edasalonexent and rare disease pipeline updates at investor day  catabasis pharmaceuticals presents positive data from part a of movedmd  catabasis pharmaceuticals presents positive preclinical data at digestive disease week   release catabasis pharmaceuticals announces positive topline phase  data for hypercholesterolemia product candidate cat  catabasis pharmaceuticals receives fda fast track designation for cat for the treatment of duchenne muscular dystrophy  catabasis pharmaceuticals announces closing of initial public offering  catabasis pharmaceuticals announces pricing of initial public offering  parent project muscular dystrophy to collaborate with catabasis pharmaceuticals inc on cat development  catabasis pharmaceuticals receives fda orphan drug designation for cat for the treatment of duchenne muscular dystrophy  catabasis pharmaceuticals announces issuance of three new us patents for cat series  catabasis describes modulation of srebp as mechanism for cat  catabasis closes  million series b financing  catabasis to present phase  data from oral smart linker conjugate cat at upcoming conference  catabasis’ cat demonstrates significant reduction of fasting and postprandial triglycerides in successful phase  trial fund clarus lifesciences ii lp sector biotechnology type private team  dennis henner cleave biosciences cleave biosciences is an early stage oncology therapeutics company focused on novel targets in cellular protein homeostasis pathways controlled largely by two distinct systems – the ubiquitin proteasome system and the autophagy system these pathways are utilized by cancer cells for their growth and survival  the company secured a m series a investment in october  cleave website fund clarus lifesciences i lp sector biotechnology type private team  nicholas j simon dennis henner michele park comentis inc comentis inc is engaged in the discovery and development of smallmolecule drugs to treat neurovascular disease indications such as alzheimer’s disease amd and cognitive disorders  the company has two fundamental technology platforms  i betasecretase inhibitors for the treatment of alzheimer’s disease and ii nach receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders comentis website  comentis and anvyl announce formation of alpharmagen a joint venture to explore nicotinic modulators fund clarus lifesciences i lp sector biotechnology type private team  scott requadt delenex therapeutics delenex therapeutics ag is a swiss biotech company developing antibody fragments for localtopical treatment of chronic and systemic treatment of acute diseases delenex was spunoff from esbatech before its acquisition by alcon in september  delenex website fund clarus lifesciences ii lp sector biotechnology type royalty interest team  robert w liptak scott requadt nicholas j simon edev edev is a special purpose vehicle that has entered into an rd project financing relationship with an undisclosed pharma company to finance multiple phase  clinical trials for additional indications of an alreadyapproved drug fund clarus lifesciences iii lp sector biotechnology type private team  nicholas galakatos entasis therapeutics entasis therapeutics was established in  with  million in startup funding from astrazeneca and all rights to astrazeneca’s industryleading discovery and early development smallmolecule antiinfectives portfolio entasis therapeutics  entasis therapeutics presents data on third drug candidate etxan orally available extendedspectrum beta lactamase inhibitor at asm microbe   entasis therapeutics names greg norden former senior vice president and chief financial officer of wyeth to its board of directors  entasis announces positive phase  data of etx for the treatment of gonorrhea  entasis presents data supporting the potential clinical utility of etx a nextgeneration betalactamase inhibitor at asm microbe   entasis announces  million series b financing led by clarus fund clarus lifesciences i lp sector biotechnology type private team  scott requadt emmett cunningham esbatech ag aquired by alcon in september  privatelyheld esbatech ag is a zurich switzerland based drug discovery and development company focused on advancing antibody fragments for therapeutic applications esbatech website fund clarus lifesciences iii lp sector biotechnology type public team  scott requadt essa pharmaceuticals nasdaq epix essa is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer with focus on advanced prostate cancer essa is developing drugs that selectively block the nterminal domain of the androgen receptor ar the ar is required for the growth and survival of most prostate cancer therefore the ar nterminal domain is an ideal target for nextgeneration hormone therapy essa website  essa pharma presents data from phase  trial of epi at  asco annual meeting  essa pharma provides business update and announces financial results for the second quarter ended march    essa pharma receives usm grant payment from cancer prevention research institute of texas  essa provides clinical study update  announces presentations at aacr  essa receives us million grant payment from cancer prevention research institute of texas  essa names peter virsik as executive vice president  chief operating officer  essa pharma inc report financial results for the second quarter ended march    essa pharma announces closing of secondary offering  essa pharma announces closing of us million private placement  essa pharma announces closing of us million private placement  essa pharma announces senior leadership changes fund clarus lifesciences ii lp sector biotechnology type private team  dennis henner emmett cunningham ferrokin biosciences inc acquired by shire plc in march  ferrokin biosciences inc a san carlos califbased company is developing an iron chelator for the treatment of ironoverload in patients with transfusiondependent hereditary and acquired refractory anemias clarus ventures has coinvested with burrill  co and celgene inc fund clarus lifesciences ii lp sector medical device type private team  robert w liptak kurt c wheeler emmett cunningham flowonix medical flowonix medical is focused on developing better treatment options for the  million americans in chronic pain more than diabetes heart disease and cancer combined  our first product for delivery of intrathecal medication the prometra® programmable implantable pump is undergoing clinical trials  flowonix is headquartered in mount olive nj flowonix website  flowonix medical inc announces fda pmas approval of prometra ii  prometra pump from flowonix medical reaches important clinical milestone fund clarus lifesciences iii lp sector biotechnology type private team  dennis henner forty seven inc with a passion for pioneering breakthrough solutions forty seven inc is committed to the advancement of immunooncology through the engagement of new and complementary phagocytic pathways that enhance antitumor efficacy and selectivity forty seven website  forty seven inc completes m series a financing and licenses technology from stanford university to advance next generation immunooncology programs fund clarus lifesciences i lp sector medical device type public team  robert w liptak kurt c wheeler globus medical inc nysegmed globus medical inc is focused on the development of products that enable spine surgeons to employ both fusion and nonfusion solutions to promote healing in patients with spinal disorders today globus is one of the fastest growing spinal implant companies in the world and a recognized leader in the development of motion sparing technology globus website  globus medical reports  first quarter results  globus medical announces acquisition of robotics developer excelsius surgical fund clarus lifesciences iii lp sector biotechnology type private team  emmett cunningham graybug vision graybug vision is developing novel products for the treatment of ocular diseases graybug vision’s technology enables the delivery of compounds to the eye up to twice per year and was codeveloped by graybug vision founder justin hanes phd who is the lewis j ort professor of ophthalmology at the wilmer eye institute of the johns hopkins university in collaboration with graybug vision cofounders and leading ophthalmology clinicianscientists from the wilmer eye institute peter a campochiaro md and peter j mcdonnell md graybug vision’s lead product gb is being developed for twice a year treatment of wet amd patients graybug vision’s second product consists of compounds with intraocular pressure lowering and neuroprotection that may be administered to the subconjunctiva twice per year for the treatment of glaucoma graybug website  graybug vision gb toxicologypk study presented at arvo   graybug vision announces  million series b financing fund clarus lifesciences iii lp sector biotechnology type private team  nicholas j simon gritstone oncology gritstone oncology is a cancer immunotherapy company developing nextgeneration personalized cancer therapeutics gritstone brings together distinguished scientific founders an experienced and diverse management team a seasoned and successful board of directors and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology immunology and immunotherapy design the company’s initial goal is to identify and deploy therapeutic neoantigens from individual patients’ tumors to develop novel treatments for lung cancer gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge ma gritstone oncology launched in october  with a series a financing of  million gritstone website  immune design and gritstone oncology announce clinical collaboration for neoantigen cancer immunotherapy fund clarus lifesciences ii lp sector biotechnology type private team  scott requadt nicholas galakatos heptares therapeutics ltd heptares is a drug discovery company focused on the discovery of novel smallmolecule drugs targeting gproteincoupled receptors gpcrs the company is deploying its proprietary star™ technology principally against highly validated but currently difficult or intractable gpcr targets in several disease areas heptares website  heptares plans relocation  new facility named the steinmetz building in honor of michael steinmetz  heptares to receive us million milestone payment from astrazeneca  heptares and leadxpro enter collaboration on powerful new approaches to gpcr structure determination for drug discovery  heptares scientists solve structures of glp and glucagon receptors enabling structurebased design for metabolic disease  heptares enters strategic drug discovery collaboration with pfizer inc focused on gpcr targets across multiple therapeutics areas  sosei acquires heptares therapeutics for up to usd  million  heptares technology enables breakthrough in drug discovery collaboration with astrazeneca  heptares extends global patent protection for gpcrfocused drug discovery platform  heptares orphan disease programme awarded grant from the uk biomedical catalyst  heptares firstinclass selective muscarinic agonists chosen as one of top neuroscience projects to watch  heptares to present on structurebased drug design using g protein coupled reception at inaugural chemistry  engineering news virtual symposium  heptares announces publication in nature of first structure of metabotropic glutamate receptor  transmembrane domain  heptares successfully completes research phase of antibody discovery collaboration with medimmune  heptares highlights potential of star® proteins as antigens for gpcrtargeted antibody discovery in new scientific publication  heptares initiates clinical study with first selective muscarinic m receptor agonist from improving cognition in patients with alzheimers disease  heptares delivers first stabilised gpcr star® to morphosys for antibody discovery  heptares achieves first research milestone in research collaboration with cubist  heptares announces publication in nature of class b gpcr structure  heptares raises us million to advance novel gpcr medicines into clinical development fund clarus lifesciences iii lp sector biotechnology type private team  dennis henner imago biosciences imago biosciences is a san franciscobased clinical development company dedicated to translating stateofthe art science into novel medicines for treating diseases that currently pose great challenges to patients their families and their physicians the company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases imago biosciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer diseasefree lives imago biosciences website fund clarus lifesciences ii lp sector biotechnology type royalty interest team  scott requadt nicholas j simon imbruvica imbruvica is an oral btkinhibitor currently under development by pharmacyclics and jj for a wide variety of bcell malignancies including chronic lymphocytic leukemiacll and mantle cell lymphoma mcl it is currently in  pivotal trials and multiple ph  trials for various relapsedrefractory and front line settings the drug has been granted three breakthrough designations by the fda and was approved for relapsedrefractory mcl in november   us food and drug administration approves imbruvica™ ibrutinib as a single agent for patients with chronic lymphocytic leukemia who have received at least one prior therapy  fda approves imbruvica for rare blood cancer  royalty pharma partners with aisling capital and clarus ventures in recent ibrutinib royalty purchase fund clarus lifesciences ii lp sector biotechnology type public team  scott requadt nicholas j simon dennis henner intercept pharmaceuticals nasdaq icpt intercept is focused on the development and commercialization of novel small molecule therapeutics to treat chronic liver disease by leveraging its expertise in bile acid chemistry  its lead candidate obaticholic acid oca is an fxr agonist that is currently in pivotal trials for primary biliary cirrhosis pbc a chronic autoimmune liver disease  oca has received orphan designation for pbc in both the us and europe  oca is also being evaluated in an nihsponsored trial for nonalcoholic steatohepatitis nash intercept website fund clarus lifesciences ii lp sector biotechnology type private team  scott requadt edward scolnick nicholas galakatos link medicine inc acquired by astrazeneca in july  link medicine is advancing diseasemodifying technologies targeted at alzheimers parkinsons and other neurodegenerative diseases where current symptomatic therapies are limited in efficacy or duration and at orphan indications which lack any meaningful symptomatic treatments fund clarus lifesciences iii lp sector biotechnology type private team  michele park lumos pharma lumos pharma based in austin texas is focused on developing novel therapies for patients with unmet medical needs in rare and neglected diseases lumos pharma is a proud awardee of the national institutes of health’s nih therapeutics for rare and neglected diseases trnd program the trnd program collaborates with biotechnology companies in the development of early stage technologies that show promise for the treatment of rare diseases the trnd program provides inkind scientific and financial support for the preclinical program to allow for the commencement of clinical trials in human subjects lumos website  lumos pharma raises  million in series b financing fund clarus lifesciences ii lp sector biotechnology type private team  nicholas j simon dennis henner lycera corporation lycera is an early stage biotechnology company developing first in class small molecule drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease  lycera’s pipeline includes proprietary small molecules against two novel targets a mitochondrial molecule that  is central to lymphocyte bioenergetics and a nuclear hormone receptor that modulates the th pathway  lycera’s small molecule drugs have the potential for best in class oral efficacy without the adverse effects of current immunosuppressive agents lycera website  lycera and celgene announce an exclusive strategic collaboration to advance novel immune modulators  lycera announces milestone in merck collaboration fund clarus lifesciences ii lp sector diagnostics  tools type public team  scott requadt william young nicholas galakatos nanostring technologies inc nasdaq nstg nanostring is a commercial stage company and an emerging leader in the expression profiling market its lead product is the only system capable of highly multiplexed direct quantification of individual mrnas in a biological sample without the use of enzymes or amplification with sensitivity below a single copy of mrna per cell high accuracy robust output and simplified workflow the nanostring platform offers investigators the benefits of the accuracy of pcr with the ability to interrogate more genes up to a thousand that would traditionally not be possible with pcr  unlike pcr or microarrays the nanostring technology affords digital results by directly imaging and counting mrnas on solid support nanostring website  nanostring technologies receives favorable final local coverage determination by palmetto gba for its prosigna breast cancer assay  nanostring announces publication in the journal of clinical oncology showing the prosigna assay identifies women with a low risk of late distant recurrence of breast cancer  nanostring collaborates with brigham and womens hospital in boston to accelerate translation of genomic discoveries into clinical diagnostics in oncology  nanostring introduces novel gene expression panel for immunooncology research  nanostring technologies releases financial results for second quarter of   nanostring technologies receives market approval from the australian therapeutic goods administration for its prosigna breast cancer prognostic gene signature assay  nanostring technologies to participate in the jefferies  global healthcare conference  nanostring technologies releases first quarter  financial results  nanostring technologies receives canadian market approval for its prosigna breast cancer prognostic gene signature assay  nanostring technologies introduces novel pancancer gene expression panel for multiplexed pathway analysis  nanostring technologies announces  million term loan agreement with capital royalty  nanostring technologies launches commercial reagents to enable laboratories to rapidly develop tests from translational research discoveries  nanostring technologies launches followon offering  nanostring technologies announces preliminary unaudited fourth quarter  revenue  nanostring launches the ncounter dx analysis system for us market  nanostring technologies releases third quarter  financial results and updates  outlook  study published showing advantages of the pam gene signature the basis for prosigna  nanostring technologies receives fda k clearance for prosigna™ breast cancer prognostic gene signature assay  nanostring technologies and bd biosciences sign collaboration agreement to develop single cell isolation and analysis workflow  nanostring technologies introduces ncounter elements™ reagents to support needs of translational research and clinical laboratory testing  results of new analysis support use of nanostring’s prosigna™ fund clarus lifesciences ii lp sector medical device type private team  kurt c wheeler emmett cunningham neomend inc acquired by bard inc in october  neomend inc based in irvine ca has developed advanced surgical sealant adhesion barrier and applicator technologies based on its proprietary protein and polymer based hydrogel platform targeted surgical procedures include thoracic spine gynecology and general surgery the companys initial product progeltm pleural air leak sealant has received fda pma approval and is the only indicated surgical sealant in the us for sealing lung air leaks in thoracic surgery progel showed statistically significant reductions in intraoperative air leaks and length of hospital stay days in the pma trial fund clarus lifesciences iii lp sector biotechnology type public team  nicholas j simon michele park neothetics nasdaq neot neothetics is a clinicalstage company developing therapeutics for the aesthetics market their initial focus is on nonsurgical localized fat reduction and body contouring the company’s lead drug candidate is for the reduction of central abdominal bulging due to subcutaneous fat in nonobese patients the company has completed phase  development for lipo and plans to launch phase  trials in early  neothetics website  neothetics initiates pivotal phase  clinical trials for lipo the first noninvasive injectable drug candidate for reduction of subcutaneous abdominal fat fund clarus lifesciences iii lp sector biotechnology type defined exit team  nicholas j simon nicholas galakatos nuvelution pharma inc nuvelution leverages its extensive knowledge experience and relationships in the pharma and biotech industries to deploy capital in risksharing collaborations with companies where product development can be facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring products to the market  nuvelution focuses on increasing rd output through risksharing collaborations fund clarus lifesciences ii lp sector biotechnology type public team  nicholas galakatos emmett cunningham ophthotech corporation nasdaq opht ophthotech corporation is a privatelyheld clinicalstage biotechnology company focused on developing and commercializing therapies for both wet and dry agerelated macular degeneration amd three new molecular entities are currently in clinical development e an antiplateletderived growth factor pdgf pegylated aptamer arc a pegylated aptamer targeting the c component of the complement cascade and volociximab a monoclonal antibody targeting the transmembrane receptor αβ integrin all three ophthotech drug products are currently in a phase  clinical trial for combination treatment with antivegf therapy lucentis® the most advanced product e has completed a phase  trial ophthotech website  ophthotech corporation achieves second  million enrollment milestone under exus licensing and commercial agreement with novartis for fovista®  ophthotech announces fovista® phase b independent analysis shows that fovista® antipdgf therapy combined with antivegf therapy is associated with a reduction of subretinal fibrosis in wet amd patients  ophthotech corporation achieves  million milestone under exus licensing and commercial agreement with novartis for fovista®  ophthotech reports second quarter  financial results and provides business update  ophthotech corporation enters into exus licensing and commercialization agreement for fovista® with novartis  ophthotech corporation receives  million in second tranche in royalty financing from novo as  ophthotech corporation prices initial public offering  ophthotech enrolls first patient in phase  clinical trial of fovista™ antipdgf therapy in combination with antivegf therapy for wet amd  ophthotech corporation files registration statement for proposed initial public offering fund clarus lifesciences i lp sector diagnostics  tools type public team  scott requadt kurt c wheeler oxford immunotec ltd nasdaq oxfd oxford immunotec ltd develops and sells clinical diagnostic products based on its patented regulatory approved tspot® technology tspot is a novel platform technology that opens up new ways of diagnosing and monitoring infections by providing a simple and extremely accurate method of studying a person’s cellular immune response to an infection oxford immunotec’s first product tspot®tb is a revolutionary new blood test for diagnosing tuberculosis infection offering unmatched sensitivity oxford website  oxford immunotec ranked among deloitte’s  technology fast ™  oxford immunotec reports third quarter  financial results  oxford immunotec acquires immunetics inc  oxford immunotec selected to test new entrants for tb in uk national tender  oxford immunotec announces ce mark approval for tspot®cmv test  oxford immunotec announces availability of the tspot®cmv test in the united states  oxford immunotec reports first quarter  financial results  oxford immunotec reports first quarter  financial results  oxford immunotec reports fourth quarter and full year  financial results  dr peter wrightonsmith named uk bioindustry association bia entrepreneur of the year  oxford immunotec announces preliminary fourth quarter and fiscal  revenue and initiates  fiscal year guidance  oxford immunotec global plc announces closing of initial public offering and exercise of overallotment option  oxford immunotec global plc announces pricing of initial public offering  oxford immunotec wins place again on the sunday times hiscox tech track  fund clarus lifesciences i lp sector biotechnology type private team  nicholas j simon kurt c wheeler emmett cunningham pearl therapeutics acquired by astrazeneca june  pearl therapeutics inc is a privatelyheld company focused on improving the treatment and prevention of widely prevalent respiratory disorders  pearl has licensed a suite of particle technologies from nektar therapeutics inc to rapidly advance their product candidates through development pearl website  pearl therapeutics to be acquired by astrazeneca for up to  billion fund clarus lifesciences ii lp sector medical device type private team  kurt c wheeler emmett cunningham restoration robotics inc restoration robotics inc a privately held medical device company is dedicated to revolutionizing the field of hair transplantation by developing and commercializing a stateoftheart imageguided system artas™ system that enables follicular unit extraction restoration robotics website fund clarus lifesciences i lp sector biotechnology type private team  dennis henner emmett cunningham sarcode inc acquired by shire in march  sarcode is a private san francisco based company focused on the development of small molecule lfa inhibitors to treat inflammatory diseases in december  sarcode secured  million in a financing coled by clarus ventures and alta partners sarcode website fund clarus lifesciences ii lp sector biotechnology type defined exit team  robert w liptak scott requadt kurt c wheeler dennis henner michele park emmett cunningham sfj pharmaceuticals inc sfj pharmaceuticals sanfranciscojapan serves as a clinical development specialty pharma company with a focus on obtaining product approval in japan targeted candidates for development in japan are low risk compounds that are already approved or have a high likelihood of approval in the us with projected japan annual sales in excess of m to date sfj has entered definitive agreements with two major global pharma companies to fund phase  trials for oncology assets predetermined milestone payments to sfj shall be received on approval of the asset in prespecified countries sfj pharmaceuticals website  besponsa apppoved in the eu for adults patients with relapsed or refractory bcell precursor acute lymphoblastic leukemia  pfizers dacomitinib wins in phase  against astrazenecas iressa  pfizer phase  study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia  eisai receives approval in japan for anticancer agent levima®  eisai launches anticancer agent lenvimatm in the united states  us fda grants priority review status to nda for anticancer agent lenvatinib  us fda grants eisai’s investigational agent lenvatinib priority review designation for the treatment of advanced thyroid cancer  eisai submits first marketing authorization application for anticancer agent lenvatinib in japan  lenvatinib phase iii results show significant improvement in progressionfree survival in patients with radioiodinerefractory differentiated thyroid cancer  phase iii trial shows lenvatinib meets primary endpoint of progression free survival benefit in treatment of radioiodinerefractory differentiated thyroid cancer fund clarus lifesciences i lp sector medical device type public team  nicholas j simon kurt c wheeler michele park sientra inc nasdaq sien sientra is a private medical device company focused on developing and marketing a broad portfolio of products within the rapidly growing plastic surgery and aesthetics market in april  sientra secured  million in a series b financing coled by clarus ventures sientra website  sientra receives fda approval  sientra® announces pricing of initial public offering fund clarus lifesciences i lp sector biotechnology type private team  scott requadt nicholas galakatos emmett cunningham taligen acquired by alexion alxn in january  taligen is a biopharmaceutical company focused on developing inhibitors of the complement system for a variety of therapeutic indications fund clarus lifesciences ii lp sector biotechnology type public team  dennis henner tetralogic pharmaceuticals inc nasdaq tlog tetralogic pharmaceuticals is a privately held biopharmaceutical company founded on a mechanism that has the potential to promote apoptosis or programmed cell death in cancer cells cancer cells are often resistant to apoptosis and tetralogic’s lead molecule a smacmimetic may abrogate that resistance the smacmimetic is currently in clinical trials for the treatment of cancer tetralogic website  tetralogic agrees to acquire shape pharmaceuticals inc  tetralogic pharmaceuticals announces new executives fund clarus lifesciences i lp sector medical device type private team  scott requadt william young tyrx acquired by medtronic inc in january  tyrx develops and commercializes proprietary polymerbased antibioticeluting medical products that prevent infection and capsular scar formation two common morbidities associated with medical device implantsit currently has  fda approved products including aigis crmd an antibioticeluting mesh envelope to prevent infections associated with the implantation of cardiac rhythm management devices crmds such as pacemakers and implantable defibrillators the company launched aigis crmd in the us in q  with its own specialty sales force tyrx website  medtronic announces ce mark and european launch of tyrxtm absorbable antibacterial envelope  medtronic announces acquisition of tyrx inc developer of solutions for surgical site infections  fda clears tyrx antibacterial envelope for use with spinal cord neuromodulators  tyrx announces first us implantation of aigisrx® r fully bioresorbable antibacterial envelope  tyrx receives fda clearance for aigisrx® neuro antibacterial envelope  tyrx receives fda clearance for fully resorbable aigisrx® r antibacterial envelope  zero infections in highrisk cardiac device replacements reported with use of tyrx antibacterial envelope  memorial care innovation fund invests in tyrx for novel technology to reduce surgical site infections fund clarus lifesciences i lp sector biotechnology type public team  scott requadt vbi vaccines nasdaq vbiv vbi is dedicated to the innovative formulationdevelopment and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets vbi’s innovative approach to vaccine development and growing pipeline address clear market opportunities and are designed to answer critical unmet medical needsvbi is aprivately held company headquartered in cambridge massachusetts with research facilities in ottawa canada vbi website  vbi vaccines announces phase  clinical program for scibvac hepatitis b vaccine  vbi vaccines completes enrollment of participants in the phase i clinical trial of its preventive cytomegalovirus vaccine candidate  scivac therapeutics and vbi vaccines announce completion of merger transaction  scivac therapeutics enters into agreement to acquire vbi vaccines  vbi vaccines announces research collaboration with sanofi pasteur to enhance vaccine stability  new study examines cmv shedding patterns in healthy cmvseropositive children  variation biotechnologies and paulson capital announce completion of merger  vbi and paulson capital merger announcement fund clarus lifesciences i lp sector biotechnology type private virdante pharmaceuticals inc assets acquired by momenta december  virdante pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases our products incorporate a proprietary “sialic switch” technology to improve the antiinflammatory properties of antibodies fund clarus lifesciences i lp sector biotechnology type public team  kurt c wheeler emmett cunningham zogenix inc nasdaq zgnx zogenix inc is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat cns disorders and pain zogenix’ initial focus is the latestage development and commercialization of intraject® sumatriptan  a needlefree singleuse disposable subcutaneous delivery system that will compete in the  billion triptan segment of the migraine market  in august  zogenix secured  million in a financing coled by clarus ventures zogenix website  zogenix announces fda approval of  mg sumavelr dosepror sumatriptan injection needlefree delivery system  zogenix and battelle expand dosepro technology business agreement  zogenix reports third quarter  financial results  zogenix receives fda approval for zohydrotm er hydrocodone bitartrate extendedrelease capsules  zogenix begins promotion of migranalr nasal spray  zogenix and valeant pharmaceuticals enter exclusive copromotion agreement for migranalrnasal spray  zogenix launches improved migraine toolbox in conjunction with national migraine awareness month boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us   east coast office    main street suite cambridge ma   miles from logan intl airport bos    facsimile   west coast office    gateway boulevard suite south san francisco ca   miles from san francisco intl airport sfo     copyright   clarus ventures llc  all rights reserved clarus ventures llc  cambridge  ma  company information products resources my account talk to a db advisor  business directory ma cambridge pharmaceutical preparations pharmaceutical preparations clarus ventures llc c clarus ventures llc claim this business  main st ste  cambridge ma  get directions   wwwclarusventurescom business info founded  incorporated annual revenue  employee count  industries pharmaceutical preparations contacts emmett cunningham contact business your email address subject message send message company summary clarus ventures llc was founded in  clarus ventures llc specializes in pharmaceutical preparations verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   c view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved clarus ventures llc private company information  bloomberg july    am et capital markets company overview of clarus ventures llc snapshot people company overview clarus ventures llc is a venture capital and private equity firm specializing in investments in seed start ups early stage mature mid venture late venture growth capital and pipes it makes investments in life sciences sector with a focus on biopharmaceuticals specialty pharma medical device research equipments biotechnology platforms or medical devices and medical technology firms with products in development at value inflection points in their lifecycle the firm prefers to invest in cancer drugs and treatments for inflammatory and urological disorders it focuses on riskshared codevelopment of latestage clinical assets and other structured financing opportunities the firm clarus ventures llc is a venture capital and private equity firm specializing in investments in seed start ups early stage mature mid venture late venture growth capital and pipes it makes investments in life sciences sector with a focus on biopharmaceuticals specialty pharma medical device research equipments biotechnology platforms or medical devices and medical technology firms with products in development at value inflection points in their lifecycle the firm prefers to invest in cancer drugs and treatments for inflammatory and urological disorders it focuses on riskshared codevelopment of latestage clinical assets and other structured financing opportunities the firm also makes investments in risksharing partnerships in which the firm will fund latestage trials of drugs being developed by large pharmaceutical companies and also in structured financing deals such as buying royalties on a drug before it is approved the firm targets investments in companies based in the united states and europe it makes investments between  million and  million per company clarus ventures was founded in  and is headquartered in cambridge massachusetts with an additional office in foster city california detailed description  main streetsuite cambridge ma united statesfounded in  phone  fax  wwwclarusventurescom key executives for clarus ventures llc dr nicholas g galakatos phd cofounder and managing director age  dr dennis j henner phd managing director  chief scientific advisor age  mr robert w liptak cpa managing director age  mr nicholas j simon iii managing director age  mr kurt c wheeler cofounder and managing director age  compensation as of fiscal year  clarus ventures llc key developments clarus ventures llc presents at nd annual neuroscience biopartnering  investment forum mar  am jan   clarus ventures llc presents at nd annual neuroscience biopartnering  investment forum mar  am venue  world trade center  greenwich st th floor d elevator bank the new york academy of sciences new york ny  united states speakers kiran reddy venture partner clarus announces executive changes jan   clarus announced the promotion of emmett cunningham jr md phd mph to managing director barry gertz md phd to partner and ari brettman md to principal with more than  years of experience in the biomedical and biopharmaceutical sectors dr cunningham joined clarus in  from eyetech pharmaceuticals inc where he was the senior vice president of medical strategy dr gertz was promoted to partner having joined clarus as a venture partner in  from merck where he was senior vice president of global clinical development overseeing all aspects of mercks clinical research dr gertz will continue in his role as chief physician scientist at nuvelution pharma inc dr brettman is a board observer for avrobio and entasis therapeutics clarus ventures llc presents at boston ceo conference may  am may   clarus ventures llc presents at boston ceo conference may  am venue four seasons boston  boylston street boston ma  united states speakers kiran reddy similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target private placement june   tisbury pharmaceuticals inc private placement january   path request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact clarus ventures llc please visit wwwclarusventurescom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close clarus ventures closes  million fund clarus ventures closes  million fund jun    et from clarus ventures llc cambridge mass and south san francisco calif june   prnewswire  clarus ventures a leading life science investment firm announced today the close of clarus lifesciences iii lp and affiliated funds clarus iii a  million fund well above its initial  million target this is the third investment fund formed and managed by clarus ventures bringing its total assets under management to more than  billion  we are thrilled by the interest both from our existing investors as well as a select group of new investors said robert liptak managing director  it is a testament to the performance of our prior funds as well as our unique and differentiated strategy clarus iii will commit an average of  million to  million per investment primarily in two areas of focus  therapeuticsfocused companies at all stages with breakthrough science andor best in class assets and  rd risksharing partnerships with the pharmaceutical and biotech industry  weve entered a promising new era of innovation in life sciences both in terms of important scientific advances as well as new business and risksharing models said scott requadt managing director  given our teams deep expertise in drug development and deal structuring clarus is wellpositioned to be a leader in both areas the clarus ventures team is led by nicholas galakatos dennis henner robert liptak scott requadt nicholas simon and kurt wheeler the team includes partners emmett cunningham and michele park principal finny kuruvilla associate ari brettman senior advisors jeff leiden and edward scolnick and venture partners barry gertz and william young snowbridge advisors acted as exclusive financial advisor to clarus and sagent advisors llc acted as placement agent about clarus ventures clarus ventures is a leading global investment firm dedicated to life sciences founded in  by a team of accomplished investment and operating professionals clarus manages over  billion invested in more than  private and public companies in the biotechnology medical device and diagnostic spaces in every investment clarus employs a handson philosophy and adheres to investment principles that are founded on core competencies in drug development complex partnership structuring and the ability to adapt to an everchanging investment landscape clarus strives to generate outstanding returns for its investors by identifying and financing innovative medicines that improve peoples lives clarus has offices in cambridge ma and south san francisco ca for more information please visit wwwclarusventurescom media contacts    sarah parker           tony russo clarus ventures            russo partners     source clarus ventures llc related links httpwwwclarusventurescom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more may    et preview clarus ventures promotes michele park phd to partner my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search boston and san francisco based health care and life science investment firm  clarus clarus investor login   home about us team portfolio investment news buzz  events contact us   about us clarus is a leading global investment firm dedicated to life sciences founded in  by a team of accomplished investment and operating professionals clarus manages over  billion and has invested in more than  private and public companies in the biotechnology medical device and diagnostic spaces in every investment clarus employs a handson approach and leverages its scientific and clinical development expertise as well as the ability to adapt to an everchanging investment landscape clarus strives to generate outstanding returns for its investors by identifying and financing innovative medicines that improve people’s lives copyright   clarus ventures llc  all rights reserved   clarus ventures llc in cambridge ma   chamberofcommercecom  sign up sign in contact us   search   near   home » massachusetts » cambridge » investment banking  securities dealers  brokers » clarus ventures llc clarus ventures llc  reviews  stars  based on  reviews  memorial dr   cambridge massachusetts    website     print  save  directions about clarus ventures llc is located at the address  memorial dr in cambridge massachusetts  they can be contacted via phone at   for pricing hours and directions clarus ventures llc has an annual sales volume of   k for more information contact robert liptak executive director or go to wwwclarusventurescomclarus ventures llc provides banking income planning cash management to its customers for maps and directions to clarus ventures llc view the map to the right for reviews of clarus ventures llc see below business features products stocks  mutual funds  municipal bonds  mortgage investments  annuities  rollover plans  government securities  tax free investments  agency bonds  commodities services cash management  business banking  corporate services  estate planning  banking  income planning  online services  wealth management   information contact information phone   website wwwclarusventurescom additional information employee size  to  exact employee count  exact sales volume  location type headquarters sales volume   k year started  categories investment banking  securities dealers  brokers real estate services finance real estate investments  securities people also viewed waddell  reed inc  sacramento st cambridge massachusetts  susan w paine  brattle st cambridge massachusetts  boston financial data services inc  columbia st cambridge massachusetts  peertransfer corporation  rd st fl  fl  cambridge massachusetts  block financial corp  fawcett st ste  cambridge massachusetts  reviews add you must sign in to post reviews by on click here to be the first to review this business  reviews   key contacts robert liptak executive director phone     cristina csimma principal phone     dennis j henner managing director phone     michael steinmetz managing director phone     nicholas galakatos managing director phone     view more     site map faq privacy policy terms of use about partners chamber partner program chamber member benefits top cities atlanta bronx brooklyn chicago cleveland dallas denver detroit houston las vegas los angeles miami minneapolis new york philadelphia phoenix saint louis san antonio san diego san jose   chamberofcommercecom bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version clarus ventures llc  locations sale  lease transaction history and property information clarus ventures llc view information on current and former clarus ventures llc building locations find leasing information previous sales and currently active for sale and lease listings of properties where clarus ventures llc is located research clarus ventures llc information location photos and more share on social networks tweet summary of clarus ventures llc related properties active sale listings  active lease listings  historical sale listings  historical lease listings  property records  nearby tenants air service corp american red cross amobee inc amr corporation applied underwriters inc automatic data processing inc avison young bio med realty trust biomed realty lp boston properties get advice from the loopnet community visit loopnet answers this loopnet clarus ventures llc tenant and owner information is organized and aggregated from public records and the millions of historical and current sale and lease listings provided by members of the loopnet commercial real estate marketplace to see how to get complete access to all of this clarus ventures llc listing and property information register for free become a free member already a member log in for sale and lease history property records clarus ventures llc has been a past or current tenant within the buildings involved in these sale and lease transactions sort by status state property type status state property type  tower lane foster city ca subleasepanoramic  views dedicated caltrain shuttle can be delivered fully furnished and wired  sf  sfyear  sfmonth  space  sf bldg  ac office building  gateway blvd s san francisco ca    sf    sfyear    sfmonth  spaces  sf bldg office building  main st cambridge ma lightfilled fully furnished offices in a variety of configurations and inclusive of full office services at cic you focus on growing you    sf negotiable negotiable  spaces  sf bldg  ac office building  tower ln foster city ca  sqftfl high image office space in the county excellent fwy access to    balconies mixed use  sf negotiable negotiable  space  sf bldg office building  main street cambridge ma short walk to kendall square red line station views of boston and charles river cafe brioche in lobby covered parking    sf  sfyear  sfmonth  space  sf bldg office building  tower lane foster city ca metro center is a multibuilding commercial property totaling approximately  square feet which includes a story office tower tw  sf negotiable negotiable  space  sf bldg office building  tower lane foster city ca metro center is a multibuilding commercial property totaling approximately  square feet which includes a story office tower tw  sf negotiable negotiable  space  sf bldg office building  tower lane foster city ca metro center is a multibuilding commercial property totaling approximately  square feet which includes a story office tower tw  sf negotiable negotiable  spaces  sf bldg office building  gateway boulevard south san francisco ca free shuttle services to airport ample free parking and loading facilities available more information on attached flyer contact cal nak  sf  sfyear  sfmonth  space  sf bldg office building no photo  gateway blvd south san francisco ca food court onsite management  sf negotiable negotiable  space  sf bldg office building  tower lane foster city ca spectacular views of the peninsula highend finishes onsite cafe onsite showers  lockers shuttle to bart and caltrain great hillsid  sf  sfyear  sfmonth  space  sf bldg office building no photo  tower lane th floor foster city ca great views from the th floor reception  window offices  conference rooms  interior offices kitchen some open area interior gl  sf  sfyear  sfmonth  space  sf bldg office building no photo  tower lane foster city ca  reantable square foot sublease divisible to  or  square feet sublease term until  spectacular views of the s not available negotiable negotiable  sf bldg office building  tower lane foster city ca  available immediately  highend finishes   fully furnished cubicles   furnished windowline private offices   interior private off  sf negotiable negotiable  space  sf bldg office building  tower lane foster city ca available in  to  days sublease through may    windowline private offices   large executive windowline private offices   sf  sfyear  sfmonth  space  sf bldg office building  main street cambridge ma riverfront office park is located at the base of the longfellow bridge in east cambridge offering spectacular views of the charles river an    sf    sfyear    sfmonth  spaces  sf bldg office building  tower lane foster city ca convenient access to three bay area airports   minutes north to san francisco international  minutes south to san jose international    sf negotiable negotiable  spaces  sf bldg office building  gateway boulevard south san francisco ca possible full building deliverable in april     sf negotiable negotiable  spaces  sf bldg office building  tower road foster city ca full commission great startup company space single suite class a tallest building in the highway  area short term sublease space te    sf    sfyear    sfmonth  spaces  sf bldg officerd  tower lane suite  foster city ca  year sublease panoramic views brand new finishes  window offices  interior offices  window conference rooms large kitchen stora  sf  sfyear  sfmonth  space  sf bldg office building page   next page contact us help add listings about us products advertise blog terms of use privacy policy  loopnet inc partners bizbuysell landandfarm bizquest clarus  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       clarus formerly known as clarus ventures llc print preview export bookmark share with colleague general information  location cambridge mass  region new england  country us  business category finance  year founded   website httpwwwclarusfundscom  lead product status na  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft aboutcom search  find it now aboutcom logo about web results the ventures surfingaboutcom surf music review  the ventures surf rocks solid rick upon that first staccato roll of the drums on “hawaii fiveo” and “walk don’t run” or that heavy rapid fire chugga chugga chugga of the guitar that opens “pipeline” you know you’re listening more » silverspotted skipper epargyreus clarus insectsaboutcom silverspotted skipper epargyreus clarus habits and traits of the silverspotted skipper the silverspotted skipper epargyreus clarus  frequents roadsides fields and backyard gardens throughout north america skippers dash quickly from flower more » venture capital  finding a venture capitalist for small business bizfinanceaboutcom if you havent worked with venture capitalists in the past examine these key considerations when working with a venture capitalist for the very first time consider the small business investment companies sbic small business investment companies are part of the small more » venture capital funds financecareersaboutcom success can be offset by many more moneylosing failures venture capital history the harvard business school alumni bulletin published a profile of the founder of modern venture capital in its june  issue georges doriot  was born more » more about web results venture capitalist roles  venture investors  biotech venture investor roles biotechaboutcom roles of venture investors what does a venture capitalist do venture capitalists vcs are investors or groups of investors that privately fund new companies usually in the technology sector in exchange for financial support called venture capital more » venture capital  what is venture capital biztaxlawaboutcom venture capital venture capital companies definition venture capital is private funding used to support risky new businesses and speculative ventures usually businesses with high growth potential a typical venture capital investment usually more » what is a venture capitalist definition sbinfocanadaaboutcom what is a venture capitalist what every startup needs to know about venture capitalists definition a venture capitalist is a person who invests in a business venture providing capital for startup or expansion the majority of venture capital vc more »           next » advertise on aboutcom    our story    news  events    careers    sitemap    all topics    reprints    help    write for about    user agreement    ethics policy    patent info    privacy policy    your ad choices      aboutcom all rights reserved